Cell Biotech Co., Ltd. (KOSDAQ:049960)

South Korea · Delayed Price · Currency is KRW

15,100

+230 (1.55%)

At close: Oct 16, 2026

Market Cap	103.34B +22.3%
Revenue (ttm)	60.40B +27.3%
Net Income	16.80B +66.1%
EPS	2,454.00 +66.0%
Shares Out	6.84M
PE Ratio	6.06
Forward PE	n/a
Dividend	600.00 (3.97%)
Ex-Dividend Date	Dec 29, 2025

Volume	7,050
Open	14,870
Previous Close	14,870
Day's Range	14,800 - 15,250
52-Week Range	11,350 - 18,500
Beta	0.47
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Cell Biotech

Cell Biotech Co., Ltd., a biotechnology company, develops lactic acid bacteria products in South Korea and internationally. It engages in the probiotics, microbiome, and anticancer new drug businesses. The company sells its products through partnerships with multinational companies and local retailers under the DUOLAC, DUOLAB, LACTOClear, and LAB2PRO brand names. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1995

Employees 101

Stock Exchange KOSDAQ

Ticker Symbol 049960

Full Company Profile

Financial Performance

In 2025, Cell Biotech's revenue was 53.13 billion, an increase of 6.44% compared to the previous year's 49.91 billion. Earnings were 10.13 billion, a decrease of -33.06%.

Financial Statements